FDA accepts resubmission of AZ’ potassium-binder
US regulators have accepted AstraZeneca unit ZS Pharma’s resubmission of ZS-9, a potassium-binding compound being developed for hyperkalaemia.
Read More
Tag: ZS Pharma
- MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
- Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
